Complementary and alternative medicine use in patients with chronic lymphocytic leukemia: an Italian multicentric surveyGiovanni D’Arena, Vincenzo De Feo, Luca Laurenti et al.|Leukemia & lymphoma/Leukemia and lymphoma|2013Cited by 26
Predictive value of the <scp>CLL</scp>‐<scp>IPI</scp> in <scp>CLL</scp> patients receiving chemo‐immunotherapy as first‐line treatmentMassimo Gentile, Fortunato Morabito, Tait D. Shanafelt et al.|European Journal Of Haematology|2018Cited by 12
Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximabMassimo Gentile, Fortunato Morabito, Tait D. Shanafelt et al.|Leukemia|2018Cited by 9
Comparison of ibrutinib and idelalisib plus rituximab in real‐life relapsed/resistant chronic lymphocytic leukemia casesFortunato Morabito, Massimo Gentile, Ernesto Vigna et al.|European Journal Of Haematology|2020Cited by 7
Richter transformation in diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia receiving ibrutinib: risk factors and outcomesSara Pepe, Francesca Romana Mauro, Candida Vitale et al.|Leukemia|2025Cited by 5